Lorundrostat hydrobromide is under clinical development by Mineralys Therapeutics and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lorundrostat hydrobromide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Lorundrostat hydrobromide overview
Mineralys Therapeutics overview
Mineralys Therapeutics. (Mineralys Therapeutics) is a private, clinical-stage biopharmaceutical company that develops novel therapy for the treatment of hypertension. Mineralys Therapeutics is headquartered in Radnor, Pennsylvania, the US.
For a complete picture of Lorundrostat hydrobromide’s drug-specific PTSR and LoA scores, buy the report here.